Testing Ultra Low Temperature Ablation for sustained ventricular tachycardia
Official title: Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
Cryoablation for Monomorphic Ventricular Tachycardia IDE Study
- 1 group
- 2 sites in Montreal
- Recruiting
Interventions
- Medical device
Ultra Low Temperature Ablation (ULTA)
ablation procedure using the investigational device (vCLAS Ventricular Ablation System including VTS Catheter and Console)
Canadian Sites (2)
2 of 2 recruiting
- Recruiting
Montreal Hear Institute
Montreal
- Recruiting
McGill University Health Centre (MUHC), Montreal General Hospital (MGH)
Montreal, Quebec
Eligibility Criteria
See who this study is looking for49 criteria
The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.
Inclusion
- +IC 1 Male or female ≥ 18 years
- +IC 2 Patients with a clinical indication for catheter ablation due to ischemic and/or non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.
- +IC 3 Any of the following:
- +Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF \< 50%.
- +non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF \< 50%
- +Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- +IC 4 Has received a market-released ICD prior to enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →
- +IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months
- +IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated/ desired due to side effectsSide effectAn unwanted effect thought to be caused by the treatment itself.Read more →)
- +IC 7 Willingness, ability, and commitment to participate in baselineBaselineYour starting measurements, taken before treatment begins.Read more → and follow-upFollow-upContinued check-ins after the treatment part is finished.Read more → evaluations for the full length of the study
- +IC 8 Willingness and ability to give an informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →
Exclusion
- −EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure
- −EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure
- −EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use
- −EC 3 VTs due to any of the following causes:
- −Idiopathic VT
- −Automaticity or triggered activity
- −Bundle Branch Reentry (BBR)
- −Any focal tachycardia (e.g., papillary, RVOT)
- −Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause
- −EC 4 NICM patients only, if any of the following apply:
- −Congenital condition that limits access to the left or right ventricles
- −Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency
- −Active inflammatory processes (e.g., myocarditis) within the past 120 days
- −Sarcoidosis
- −Hypertrophic cardiomyopathy
- −Drug- or alcohol-induced cardiomyopathy
- −EC 5 Any VT ablation within 4 weeks prior to enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →
- −EC 6 More than one prior (\>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years
- −EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT
- −EC 8 Any other cardiovascular conditions as described below:
- −Class IV heart failure
- −Aortic aneurysm
- −Interatrial baffle, closure device, patch, or PFO occlusion device
- −Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure
- −Acute MI or unstable angina in the previous 60 days
- −Mechanical mitral or aortic valve
- −Cardiac myxoma
- −Significant congenital heart disease
- −EC 9 Acute illness or active systemic infection
- −EC 10 Any previous history of cryoglobulinemia
- −EC 11 History of blood clotting or bleeding disease
- −EC 12 Peripheral vascular disease that precludes LV access
- −EC 13 Contraindication to heparin
- −EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.
- −EC 17 Current enrollment in any other study protocolProtocolThe detailed plan a study must follow.Read more → where testing or results from that study may interfere with the procedure or outcome measurements for this study
- −EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)
- −EC 16 Pregnant, or anticipated pregnancy during study follow-upFollow-upContinued check-ins after the treatment part is finished.Read more →
- −Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure
In plain language
Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.
What this study is
This study is testing a treatment for a condition.
This study is not organised into the usual phase numbers — that is common for device, behavioural, and diagnostic research.
From the trial registry
Built from these fields:
- designModule.designInfo.primaryPurpose
- designModule.phases
Who receives what
Everyone in this study is in one group and receives Ultra Low Temperature Ablation (ULTA).
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].label
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
How the study is run
There is only one group in this study, so there is no assignment to different treatments.
This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.
From the trial registry
Built from these fields:
- designModule.designInfo.allocation
- designModule.designInfo.maskingInfo.masking
Is there a placebo?
This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for
The study lists a minimum age of 18 years, with no upper limit given.
The study is open to people of any sex.
The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.
From the trial registry
Built from these fields:
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How big and how long
The study aims to enrol about 100 people.
The study is currently expected to finish around September 2027.
The main measurement is taken over: 7 days following the ablation procedure.
From the trial registry
Built from these fields:
- designModule.enrollmentInfo.count
- statusModule.completionDateStruct.date
- outcomesModule.primaryOutcomes[].timeFrame
What the study measures
Primary Safety EndpointEndpointThe specific thing a study measures to answer its question.Read more → - Freedom from definite or probable device or procedure related Major Adverse EventsAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (MAEs) that occur within 7 days following the ablation procedure — measured over 7 days following the ablation procedure.
Primary Efficacy Endpoint - Freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure — measured over 6 months after the procedure.
Primary Procedural Endpoint - Percentage of non-inducibility VT targeted for ablation post-procedure — measured over at the end of the ablation procedure.
From the trial registry
Built from these fields:
- outcomesModule.primaryOutcomes[].measure
- outcomesModule.primaryOutcomes[].timeFrame
Source: NCT07650032 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.
Not medical advice. What do these terms mean?
What is being tested — in plain terms
About Ultra Low Temperature Ablation (ULTA)Device
ablation procedure using the investigational device (vCLAS Ventricular Ablation System including VTS Catheter and Console)
From the trial registry — its own words, unedited.
What a device is here: A physical instrument, implant, app or piece of equipment being studied.
Read the full explanation → · in clinical review
Common questions
Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.
Am I eligible for this trial?
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.
What the study lists: a minimum age of 18 years.
The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.
The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.eligibilityCriteria
Is there a placebo?
This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.
From the trial registry
- armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?
This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.
There is only one group in this study, so there is no assignment to different treatments.
From the trial registry
- designModule.designInfo.maskingInfo.masking
- designModule.designInfo.allocation
Who can join?
The study lists a minimum age of 18 years, with no upper limit given.
It is open to people of any sex.
It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How long would this take?
The study's main measurement is taken over: 7 days following the ablation procedure.
The study as a whole is currently expected to finish around 2027-09-30.
How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.
From the trial registry
- outcomesModule.primaryOutcomes[].timeFrame
- statusModule.completionDateStruct.date
How many people are taking part?
The study aims to enrol about 100 people.
From the trial registry
- designModule.enrollmentInfo.count
Where is this happening?
This study lists 3 locations, including: Montreal, Canada; Montreal, Quebec, Canada; Staten Island, New York, United States.
Sites can open and close during a study, so confirm with the team before travelling.
From the trial registry
- trial_locations
About This Trial
The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio Medical vCLAS Ventricular Ablation System (including VTS Catheter and Console) in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)
Other Sites (1)
Northwell Health- Staten Island University Hospital
Staten Island, New York, United States
Think this trial might be right for you?
Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.
See if this trial could fit youThis page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.